NCT06899243尚未招募不适用
The Effect of CL22205 on Bone Mineral Density and Menopausal Symptoms in Women: A Randomized, Double-blind, Placebo Controlled Clinical Trial
Eetho Brands, Inc0 个研究点目标入组 80 人开始时间: 2025年3月25日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 80
- 主要终点
- Change from baseline to the end of the study period in : Bone Mineral density (BMD) (g/cm2) of Lumbar spine (L1-L4)
研究概览
简要总结
The purpose of this study is to evaluate the effect of CL22205 on bone mineral density and menopausal symptoms in women.
详细描述
A total of 80 healthy female subjects aged between 55 and 65 years will be included in the study. Assessment of inclusion and exclusion criteria will be done based on clinical and laboratory investigations. The eligible subjects will be randomized as per the computer-generated randomization list. The subjects will be assigned to either CL22205 - 200 mg or placebo arms at 1:1 ratio. The subjects will be instructed to take one capsule a day after breakfast for 360 days. Apart from primary and secondary outcomes, the study will also record the vital signs and adverse events to evaluate the herbal composition's safety and tolerability. The safety assessment of the CL22205 will also include routine laboratory investigations on blood, urine and clinical chemistry at screening and the final visit of the intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 55 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy females aged between 55 and 65 years with a Body mass index (BMI) of approximately 24 and 29 kg/m
- •Women with menopausal symptoms (modified Kupperman index scores 15-29), absence of menstrual cycle for past 12-months; follicle-stimulating hormone (FSH) > 30 mIU/mL; estradiol < 30 pg/mL.
- •Subjects who are under standard supplementation of Vitamin D3 (cholecalciferol) and calcium carbonate.
- •Subjects with osteopenia (T score of spine between -1 and -2.5 in DEXA).
- •Must also be experiencing at least two symptoms of menopause, such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, weight gain, or vaginal changes.
- •Subject understands the study procedures and provides signed informed consent to participate in the study.
- •Normal vital signs, including electrocardiogram (ECG) and laboratory evaluations (including clinical biochemistry, haematology, lipid profile, thyroid profile and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.
排除标准
- •Consumption of functional food or supplement that modifies body composition, during or 6 months prior to the study.
- •History of cerebrovascular disease, thrombo-embolic disorders, heart attack, or angina at any time or thrombophlebitis within the last 5 years.
- •Subjects on anti-coagulant or anti-platelet drugs on a daily basis for any conditions.
- •Presence of chronic diseases that prevent the performance of a physical exercise program (disabling arthropathies, moderate / severe chronic lung disease, arrhythmias, etc.).
- •High alcohol intake (>2 standard drinks per day), or recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or psychiatric drug users.
- •Smokers or tobacco users.
- •Inability to understand informed consent.
- •Serious or terminal illnesses.
- •Fasting blood glucose level >125 mg/dl.
- •Subjects with a high blood pressure at screening (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg).
- •Subjects who had any hormonal therapy, metformin or any other herbal products in the past 3 months.
- •Hypothyroidism, hyperthyroidism, hyperprolactinemia, Cushing's syndrome and congenital adrenal hyperplasia, following a special diet for the past 3 months.
- •Taking drugs affecting insulin sensitivity or lipid and hormonal profiles, including glucocorticoids, ovulation-stimulating drugs, anti-obesity, anti-diabetes, anti-hypertensive, anti-estrogenic, anti-androgenic during the last 3 months (except the usual drugs of the subjects).
- •Active gall bladder disease, gynaecological (including hysterectomy) or breast surgery in the last 6 months.
- •Subjects who are being treated for liver cancer or cirrhosis, chronic renal failure, congestive heart failure.
- •Subjects with a systemic disease including tuberculosis, leucosis, collagenosis, multiple sclerosis or other autoimmune diseases.
- •History of breast, endometrial, other gynaecological cancer at any time or other cancer within the last 5 years.
- •History of hypersensitivity reactions attributed to investigational product (IP) or its components or related products.
- •History of positive hepatitis screening including Hepatitis B surface antigen or Hepatitis C virus (HCV) antibodies or subjects with human immunodeficiency virus (HIV) and /or syphilis.
- •History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.
- •Participated in a clinical study with an investigational drug or biologic within the last 30 days.
- •Any condition that in opinion of the investigator, does not justify the subjects' participation in the study.
研究组 & 干预措施
CL22205
Experimental
200 mg, One capsule a day after breakfast for 360 days
干预措施: CL22205 (Dietary Supplement)
Placebo
Other
One capsule a day after breakfast for 360 days
干预措施: Placebo (Other)
结局指标
主要结局
Change from baseline to the end of the study period in : Bone Mineral density (BMD) (g/cm2) of Lumbar spine (L1-L4)
时间窗: Screening/Baseline, Days 180 & 360
A low-dose X-ray is used to assess the bone mineral content (density) in specific areas, such as the lumbar spine at L1-L4 region. The results are typically expressed in terms of the T-score. If T scores ≥-1 signifies healthy bone, a range from -1 to -2.5 indicates osteopenia and a score of ≤-2.5 indicates osteoporosis.
次要结局
- Change from baseline to the end of the study period in: Profile of Mood States (POMS-SF)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in: Female Sexual Function Index (FSFI)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in: Pittsburgh Sleep Quality Index (PSQI)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Menopause Symptoms' Severity Inventory (MSSI-38)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Lean body mass through DEXA(Screening/Baseline, Days 180 & 360)
- Change from baseline to the end of the study period in : Scores of modified Kupperman index (mKI)(Screening, Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in: Hand grip-strength(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in: Chalder Fatigue Scale (CFS)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in: Vaginal dryness(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Gastrointestinal symptoms questionnaire (GIS)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Mini Cog Questionnaire (Cognitive function)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Subject's self-assessment of skin Questionnaire(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Scores of subjective self-assessment on hair quality(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Nail quality related questionnaire (NailQoL)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Perceived Stress Scale (PSS-10)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Visual assessment of skin wrinkles(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Core Lower Urinary Tract Symptom score (CLSS)(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in: Vaginal pH(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Skin hydration using moisture meter(Baseline/Day 1, Days 90,180 & 360)
- Change from baseline to the end of the study period in : Bone specific serum ALP(Baseline/Day 1 & Day 360)
- Change from baseline to the end of the study period in : Serum Osteoprotegerin(Baseline/Day 1 & Day 360)
- Change from baseline to the end of the study period in : Serum Osteocalcin(Baseline/Day 1 & Day 360)
- Change from baseline to the end of the study period in: Serum cortisol(Baseline/Day 1 & Day 360)
研究者
相似试验
已完成
2 期
Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without IbandronateOsteoporosis, PostmenopausalNCT04321837Columbia University60
已完成
不适用
Efficacy of SGLT2 inhibitors on bone mineral density in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000016921Akishima Clinic120
已完成
不适用
Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate CancerOsteoporosisNCT00536653Wirral University Teaching Hospital NHS Trust618
已完成
不适用
Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast CancerBreast CancerOsteoporosisNCT00587925Memorial Sloan Kettering Cancer Center7
招募中
不适用
Changes in bone mineral density and serum calcium levels after romosozumab treatmet in postmenopausal osteoporosis patients:About short-term results at 6 monthsprimary osteoprosisosteoprosisD010024JPRN-jRCT1040190111Kobayakawa Tomonori60